GeneDx (NASDAQ: WGS) shares fell Wednesday. The company, a leader in delivering improved health outcomes through genomic insights, continues its investment in advancing scientific discovery through understanding gene-disease relationships, contributing to more than 85 peer-reviewed publications in 2024. These contributions, added to GeneDx’s years of dedicated research efforts, influenced the broadening of phenotypes, the discovery of new disease mechanisms and new modes of inheritance, and ultimately impacted results of 12% of all patients who have received exome or genome sequencing from GeneDx.
In 2024, GeneDx also contributed nearly one quarter of all submissions to GeneMatcher, a platform that facilitates disease-gene discovery by sharing genetic findings among patients, clinicians, and researchers. For each “candidate gene”—a gene that is highly suspected (but not yet proven) to be linked to a specific disease—identified by GeneDx, the lab submits the finding to GeneMatcher, which then connects researchers and clinicians around the world so they can work together to better understand genetic contributions to rare disease. To date, this research has impacted >22,000 patients tested at GeneDx and, in the future, will influence the results of many additional patients seeking diagnoses or answers.
WGS shares capsized $3.56, or 3.7%, to $93.48.
